Modern Views and Analysis of Promising Approaches to the Treatment of Melanoma
https://doi.org/10.33647/2074-5982-19-3-47-52
Abstract
Melanoma is a malignant tumor that can rapidly develop resistance to treatment because of its high mutational activity. The introduction of tyrosine kinase receptor inhibitors (BRAF, MEK) and cytotoxic T lymphocyte antigen/receptor inhibitors (CTLA4, PD-1) into clinical practice has led to an increase in patient survival rates. In in vitro studies, combining PIK3 and MEK inhibitors demonstrate a pronounced reduction in tumor cell growth. The phenomenon of synthetic lethality is also promising, allowing the high mutational load of melanoma to be used as a tool for the development of more effective drugs.
About the Authors
A. V. Safronenko
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Andrey V. Safronenko, Dr. Sci. (Med.), Prof.
344037, Rostov-on-Don, Nahichevansky Ave., 29
O. M. Kudelina
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Oksana M. Kudelina, Cand. Sci. (Med.)
344037, Rostov-on-Don, Nahichevansky Ave., 29
E. V. Gantsgorn
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Elena V. Gantsgorn, Cand. Sci. (Med.), Assoc. Prof
344037, Rostov-on-Don, Nahichevansky Ave., 29
M. Kh.-B. Buraeva
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Maret Kh.-B. Burayeva
344037, Rostov-on-Don, Nahichevansky Ave., 29
M. Kh.-B. Buraeva
National Medical Research Centre for Oncology of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Malika Kh.-B. Burayeva, Resident
344037, Rostov-on-Don, 14-th Line Str., 63
A. A. Miteneva
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Anna A. Miteneva
344037, Rostov-on-Don, Nahichevansky Ave., 29
L. R. Shvelidze
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Luka R. Shvelidze
344037, Rostov-on-Don, Nahichevansky Ave., 29
D. A. Kalmykova
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Darya A. Kalmykova
344037, Rostov-on-Don, Nahichevansky Ave., 29
A. A. Ilyina
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Alisa A. Ilyina
344037, Rostov-on-Don, Nahichevansky Ave., 29
V. Z. Lachinov
Rostov State Medical University of the Ministry of Health Care of Russia
Russian Federation
Russian Federation
Vadim Z. Lachinov
344037, Rostov-on-Don, Nahichevansky Ave., 29
References
1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М., МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022:252. [Kaprin A.D., Starinskii V.V., Shahzadova A.O. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost') [Malignant neoplasms in Russia in 2021 (morbidity and mortality)]. Moscow: National Medical Research Radiological Centre of the Ministry of Health Care of Russia, 2022:252. (In Russian)].
2. Ассоциация онкологов России, Ассоциация специалистов по проблемам меланомы, Общероссийская общественная организация «Российское общество клинической онкологии». Меланома кожи и слизистых оболочек: клинические рекомендации. М., 2020. [Association of Oncologists of Russia, Russian Melanoma Professional Association “Melanoma. PRO”, Russian Society of Clinical Oncology. Melanoma kozhi i slizistykh obolochek: klinicheskie rekomendatsii [Melanoma of the skin and mucous: Clinical guidelines]. Moscow, 2020. (In Russian)].
3. Стукань А.И., Горяинова А.Ю., Шаров С.В. Причины резистентности к PARP-ингибированию и возможности её преодоления. Клинический случай агрессивного течения BRCA-ассоциированного рака молочной железы. Опухоли женской репродуктивной системы. 2022;18(1):54–65. [Stukan’ A.I., Goryainov A.Yu., Sharov S.V. Prichiny rezistentnosti k PARP-ingibirovaniyu i vozmozhnosti ee preodoleniya. Klinicheskiy sluchay agressivnogo techeniya BRCAassotsiirovannogo raka molochnoy zhelezy [Causes of resistance to PARP inhibitors and ways to overcome it. Case report of aggressive BRCA-related breast cancer]. Opukholi zhenskoy reproduktivnoy sistemy [Tumors of female reproductive system]. 2022;18(1):54–65. (In Russian)]. DOI: 10.17650/1994-4098-2022-18-1-54-65.
4. Hartman G.D., Lambert-Cheatham N.A., Kelley M.R., Corson T.W. Inhibition of APE1/Ref-1 for neovascular eye diseases: From biology to therapy. Int. J. Mol. Sci. 2021;22(19):10279. DOI: 10.3390/ijms221910279.
5. Lelliott E.J., McArthur G.A., Oliaro J., Sheppard K.E. Immunomodulatory effects of BRAF, MEK, and CDK4/6 inhibitors: Implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma. Front. Immunol. 2021;12:661737. DOI: 10.3389/fimmu.2021.661737.
6. Li S., Fu J., Yang J., Ma H., Bhutani D., Mapara M.Y., Marcireau C., Lentzsch S. Targeting the GCK pathway: A novel and selective therapeutic strategy against RAS-mutated multiple myeloma. Blood. 2021;137(13):1754–1764. DOI: 10.1182/ blood.2020006334.
7. Schuler M., Zimmer L., Kim K.B., Sosman J.A., Ascierto P.A., Postow M.A., De Vos F.Y.F.L., van Herpen C.M.L., Carlino M.S., Johnson D.B., Berking C., Reddy M.B., Harney A.S., Berlin J.D., Amaria R.N. Phase Ib/II trial of ribociclib in combination with binimetinib in patients with NRAS-mutant melanoma. Clin. Cancer Res. 2022;28(14):3002–3010. DOI: 10.1158/1078-0432.CCR-21-3872.
8. Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D., Cowey C.L., Schadendorf D., Wagstaff J., Dummer R., Ferrucci P.F., Smylie M., Butler M.O., Hill A., Márquez-Rodas I., Haanen J.B.A.G., Guidoboni M., Maio M., Schöffski P., Carlino M.S., Lebbé C., McArthur G., Ascierto P.A., Daniels G.A., Long G.V., Bas T., Ritchings C., Larkin J., Hodi F.S. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 2022;40(2):127–137. DOI: 10.1200/JCO.21.02229.
Review
For citations:
Safronenko A.V., Kudelina O.M., Gantsgorn E.V., Buraeva M.Kh., Buraeva M.Kh., Miteneva A.A., Shvelidze L.R., Kalmykova D.A., Ilyina A.A., Lachinov V.Z. Modern Views and Analysis of Promising Approaches to the Treatment of Melanoma. Journal Biomed. 2023;19(3):47-52. (In Russ.) https://doi.org/10.33647/2074-5982-19-3-47-52
Views:
373
Email this article 
